AI Article Synopsis
- Losartan is an angiotensin II receptor blocker used for managing high blood pressure and cardiovascular issues, but it can rarely cause liver damage.
- A case involving a 54-year-old man showed severe liver injury and sub-fulminant hepatitis linked to losartan, characterized by symptoms like abdominal pain, jaundice, and altered mental state.
- The patient improved after stopping losartan and receiving treatment, highlighting the need for awareness of losartan's potential hepatotoxic effects.
Article Abstract
Losartan is a widely prescribed angiotensin II receptor blocker (ARB) used for the management of hypertension and various cardiovascular conditions. While it is generally considered a safe medication, rare cases of hepatotoxicity have been reported in the literature. We present a case of severe hepatic injury and sub-fulminant hepatitis attributed to losartan use in a 54-year-old male patient with underlying hypertension. He presented with a two-week history of abdominal pain, progressive jaundice, dark urine, and vomiting, followed by altered sensorium. His clinical picture, serology, and imaging findings confirmed a severe hepatic injury. After ruling out all possible causes, he was diagnosed with drug-induced hepatotoxicity with losartan treatment. He started improving gradually after losartan discontinuation, N-acetylcysteine administration, and supportive management with close monitoring of liver enzymes. This case report aims to underscore the importance of recognizing losartan as one of the potential causes of hepatotoxicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758354 | PMC |
| http://dx.doi.org/10.7759/cureus.49846 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!